More money is being funneled into science based startups, especially fledgling companies in the biotech sector.

A report in The New York Times by Hiroko Tabuchi explained that “investments in biotechnology start-ups rose 26 percent in the first half of 2014, to $2.93 billion, from the period a year earlier and is on track to exceed the 2008 peak of $5.14 billion.”

Tabuchi writes that a possible explanation for this uptick in funding for science startups is a “growing feeling” among investors that Silicon Valley’s best and brightest are steering clear of the world’s biggest problems.